Recent News

February 26, 2021

Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent

February 22, 2021

Oncology Pharma Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology

February 16, 2021

Oncology Pharma is Pleased to Welcome New Chairman to its Scientific Advisory Board

 

February 9, 2021

Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for its Connect2Med Clinical Trials Platform

 

 

February 3, 2021

Oncology Pharma Extends its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology

January 28, 2021

Oncology Pharma Announces the Appointment of New Chief Financial Officer

 

August 27, 2020

Oncology Pharma Announces Extension of Letter of Intent with Kalos Therapeutics, Retained an Interim CEO and Approval of Reverse Stock Split

 

 

April 21, 2020

Oncology Pharma Licensor and Co-Development Partner, Kalos Therapeutics, Announces Progress in Covid-19 Preventative & Therapeutic Approaches

April 6, 2020

Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID-19

March 11, 2020

 

Oncology Pharma Continues Licensing Agreement with NanoSmart

 

 

January 28, 2020

Oncology Pharma, Inc. Narrows Focus on Funding Efforts

2019

 

December 26, 2019

Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Investment Partners, Ltd.